Immune-related tumor response assessment criteria: a comprehensive review.

about

P2860

Q58779424-E9BD2069-012D-4E03-B6CC-05EA07BE8A88

P2860

Immune-related tumor response assessment criteria: a comprehensive review.

Item

http://www.wikidata.org/entity/Q49668388

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Immune-related tumor response assessment criteria: a comprehensive review.

@en

Immune-related tumor response assessment criteria: a comprehensive review.

@nl

type

Item

label

Immune-related tumor response assessment criteria: a comprehensive review.

@en

Immune-related tumor response assessment criteria: a comprehensive review.

@nl

prefLabel

Immune-related tumor response assessment criteria: a comprehensive review.

@en

Immune-related tumor response assessment criteria: a comprehensive review.

@nl

P1476

Immune-related tumor response assessment criteria: a comprehensive review.

@en

P2093

Avinash Kambadakone

http://www.w3.org/2001/XMLSchema#string

Bhanusupriya Somarouthu

http://www.w3.org/2001/XMLSchema#string

Cheryl A Sadow

http://www.w3.org/2001/XMLSchema#string

Gordon J Harris

http://www.w3.org/2001/XMLSchema#string

Susanna I Lee

http://www.w3.org/2001/XMLSchema#string

Trinity Urban

http://www.w3.org/2001/XMLSchema#string

P2860

Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC

Nivolumab plus ipilimumab in advanced melanoma.

The blockade of immune checkpoints in cancer immunotherapy

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Reporting results of cancer treatment

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

P304

20170457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1259/BJR.20170457

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29172675

http://www.w3.org/2001/XMLSchema#string

P932

5966001

http://www.w3.org/2001/XMLSchema#string

Immune-related tumor response assessment criteria: a comprehensive review.

about

P2860

P2860

Immune-related tumor response assessment criteria: a comprehensive review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P932